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The ATBF1/ZFHX3 gene at 16q22 is the second most frequently mutated gene in human prostate cancer and has
reduced expression or mislocalization in several types of human tumors. Nonetheless, the hypothesis that ATBF1
has a tumor suppressor function in prostate cancer has not been tested. In this study, we examined the role of
ATBF1 in prostatic carcinogenesis by specifically deleting Atbf1 in mouse prostatic epithelial cells. We also
examined the effect of Atbf1 deletion on gene expression and signaling pathways in mouse prostates.
Histopathologic analyses showed that Atbf1 deficiency caused hyperplasia and mouse prostatic intraepithelial
neoplasia (mPIN) primarily in the dorsal prostate but also in other lobes. Hemizygous deletion of Atbf1 also
increased the development of hyperplasia and mPIN, indicating a haploinsufficiency of Atbf1. The mPIN lesions
expressed luminal cell markers and harbored molecular changes similar to those in human PIN and prostate
cancer, including weaker expression of basal cell marker cytokeratin 5 (Ck5), cell adhesion protein E-cadherin, and
the smooth muscle layer marker Sma; elevated expression of the oncoproteins phospho-Erk1/2, phospho-Akt and
Muc1; and aberrant protein glycosylation. Gene expression profiling revealed a large number of genes that were
dysregulated by Atbf1 deletion, particularly those that encode for secretory and cell membrane proteins. The four
signaling networks that were most affected by Atbf1 deletion included those centered on Erk1/2 and IGF1, Akt and
FSH, NF-κB and progesterone and β-estradiol. These findings provide in vivo evidence that ATBF1 is a tumor
suppressor in the prostate, suggest that loss of Atbf1 contributes to tumorigenesis by dysregulating membrane
and secretory proteins and multiple signaling pathways, and provide a new animal model for prostate cancer.
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The AT-motif binding factor 1/zinc finger homeobox 3 (ATBF1/
ZFHX3) gene encodes a large protein structurally characterized by
multiple zinc-finger motifs and four homeodomains [1]. ATBF1
appears to play a role in neuronal differentiation and cell death [2–4],
atrial fibrillation [5,6], and embryonic development [7]. ATBF1
could be a tumor suppressor in several organs including the prostate,
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frequently occurs in cancer cells, which can inactivate tumor suppressor
genes (TSGs) and thus contribute to tumorigenesis [8]. Our previous
characterization of 16q22 deletion and mutational screening identified
ATBF1 as a candidate TSG as it has frequent deletion and somatic
mutations in prostate cancer [9]. Recent genome-wide sequencing of
castration-resistant prostate cancer indicated that ATBF1 is the second
most frequently mutated gene in human prostate cancer [10]. ATBF1
mutation is also frequent in endometrial cancers [11] and the ATBF1
locus is frequently deleted in breast cancers [12]. A germline variant of
ATBF1 is linked to increased risk of sporadic prostate cancer [13] and
ATBF1 expression is significantly reduced in breast cancer [12,14],
hepatocellular carcinoma [15], gastric cancer [16,17], and two
transgenic mouse models of prostate cancer, TRAMP-ARpe-T877A/Y
and ARR2PB-c-myc [18,19]. Reduced expression and/or mislocalization
of ATBF1 protein has been detected in several types of cancer
[14,20,21]. These alterations are associated with worse patient survival
in breast cancer and histopathologic progression in head and neck
cancer [14,21].
While these studies suggest a tumor suppressor function for ATBF1
in human cancer, this hypothesis has not been tested in animal models.
How ATBF1 might suppress carcinogenesis has not been determined,
although as a transcription factor ATBF1 has been shown to regulate the
expression of several differentiation or tumor-related genes including
AFP, aminopeptidase N, neurod1, MUC5AC and p21WAF1 [4,22–25].
Few mouse models are truly relevant to human prostate cancer by
neoplastic phenotypes and/or genetic causes [26] but models still
provide a powerful platform for understanding prostate cancer biology
and developing novel therapies against prostate cancer.
In this study, we examined ATBF1 function in a knockout mouse
model. Using the Cre-loxP system, we deleted Atbf1 specifically in
mouse prostatic epithelium (PE) and found that inactivation of Atbf1
caused hyperplasia and mouse prostatic intraepithelial neoplasia
(mPIN), primarily in the dorsal prostate (DP). A number of
molecular alterations resembling those in human prostate cancer were
detected in Atbf1 deletion-induced prostatic lesions. Furthermore,
Atbf1 deletion dysregulated the expression of a large number of
genes involved in multiple signaling pathways, particularly those that
encode for secretory proteins and membrane proteins.Methods and Materials
Ethics Statement
All animal work was performed in compliance with relevant regulatory
standards and was approved by the Institutional Animal Care and Use
Committee of Emory University.
Mouse Experiments
The PB-Cre4 transgenic mouse line was obtained from the NCI
Mouse Models of Human Cancers Consortium (MMHCC, Frederick,
MD, Cat#: 01XF5). Floxed Atbf1 mice (Atbf1flox/wt), in which the
Atbf1 genomic DNA from exon 7 to exon 8 was flanked with loxP
sequences, were generated in our previous study [7] and maintained on a
mixed background of C57BL/6 J and 129Sv/J. Atbf1flox/+;PB-Cre+
(Atbf1PE+/-) mice were made by first crossing PB-Cre+/- male mice with
Atbf1flox/+ female mice, then crossing Atbf1flox/+;PB-Cre+ male mice with
Atbf1flox/+female mice to obtain mice with all the desired genotypes.
Atbf1+/+;PB-Cre+ (Atbf1PE+/+) male mice were examined as controls
for different groups at different ages. Six Atbf1+/+;PB-Cre - malemice were also used as controls. All mice were genotyped by PCR
using genomic DNA isolated from tail biopsies [7]. Alleles of
Atbf1 flox (1248 bp), Atbf1wt (1071 bp) and Atbf1Δ7&8 (289 bp)
were distinguished based on the size of their PCR products
using primers 5’-GGCCCTTGACTGCATTTCTTTCCTGT-3’
and 5’-ATTCGTTAATGGGAAGGTGTCAGA-3’. Primers used for
genotyping the Cre gene were 5’-CTGAAGAATGGGACAGG
CATTG-3’ and 5’-CATCACTCGTTGCATCGACC-3’ (393 bp).
Histological Analysis, Immunohistochemical (IHC) Staining,
Immunofluorescence (IF) Staining, and Special Staining
Prostatic tissues were surgically harvested and fixed in 4%
formaldehyde overnight. Prostatic lobes were then dissected, embedded in
paraffin, and sectioned at 5-μmthickness. Standard hematoxylin and eosin
(H&E) staining was performed for histological analyses. Pathological
diagnosis was performed by Dr. Henry F. Frierson and confirmed by
Dr. Robert D. Cardiff via a paid service at the Center for
Comparative Medicine, Department of Pathology, University of
California at Davis. Previously established criteria for mouse
prostatic lesions were followed [27,28].
For IHC staining, tissue sections were deparaffinized, rehydrated,
and washed in PBS. Antigen retrieval was done by heating slides in a
microwave oven for 15 min or in a pressure cooker for 3 min in
citrated buffer (pH 6.0, 10 mM trisodium citrate). After blocking
with 5% normal goat serum in Tris-buffered saline with 0.1% Tween-
20 (TBST), tissue sections were incubated with primary antibodies at
4°C overnight, followed by incubation with EnVision Polymer-HPR
secondary antibodies (Dako, Glostrup, Denmark) at room temperature
for 40min. After the application ofDAB-chromogen, tissue sectionswere
mounted and visualized under microscopes. Representative slides were
scanned with Nanozoomer 2.0HT (Hamamatsu, Bridgewater, NJ), and
pictures were captured using NDP.view software (Hamamatsu). Primary
antibodies used in this study included anti-Ki67 (Lab Vision, Fremont,
CA), anti-cytokeratin 5 (Covance, Princeton, NJ), anti-cytokeratin18
(Abcam, Cambridge, MA), anti-Ar, anti-Sma (Sigma-Aldrich, St. Louis,
MO), anti-synaptophysin (Invitrogen, Carlsbad, CA), anti-Cdh1,
anti-phospho-Erk1/2, anti-phospho-Akt, and anti-Spink3 (Cell
Signaling Technology, Billerica, MA), anti-Muc1 (Thermo Scientific,
Waltham, MA), and anti-clusterin (Santa Cruz Biotechnology,
Dallas, TX).
For immunofluorescent staining, tissue slides were prepared and
incubated with primary antibodies as described above. Appropriate
Alexa Fluor fluorochrome-conjugated secondary antibodies
(Invitrogen) were used, and nuclei were counterstained with 4’,6-
diamidino-2-phenylindole (DAPI) for 5 min. Slides were mounted
and visualized under fluorescent microscopes (Zeiss, Thornwood,
NY). Primary antibodies included anti-Atbf1, anti-Tn, and
biotinylated-HPA [21,29]. Special staining, including Periodic
acid-Schiff (PAS) and Alcian blue, was performed by the Emory
University Department of Pathology.
Proliferation Assay
Tissue sections of mouse prostates were immunostained with the
anti-Ki67 antibody to detect cells that expressed the Ki67 proliferation
marker. Slides were then scanned with theNanozoomer 2.0HT scanner
for cell counting. For each individual mouse, the number of Ki67-
positive epithelial cells and the number of total epithelial cells in the
dorsal prostate (DP) were determined using the ImageJ program [30].
The percentage of Ki67-positive epithelial cells in a DP was then
Figure 1. Design and confirmation of Atbf1 deletion in mouse prostates. (A) Schematic of PB-Cre-mediated Atbf1 deletion in mouse
prostates. Engineered Atbf1 genomic DNA from exon 6 to exon 10 is shown at the top (wildtype allele). The LoxP and Frt sequences are
marked by triangle- and diamond-shaped boxes respectively. Locations of genotyping primers are indicated by arrowheads. PB-Cre-
mediated deletion of exons 7 and 8 generates the null allele (Atbf1Δ7&8). (B) Prostate-specific deletion of the Atbf1 gene was confirmed by
genotyping PCR in a 9-week-old Atbf1flox/wt;PB-Cre+ (Atbf1PE+/-) mouse. While the Atbf1flox (1248 bp) and Atbf1wt (1071 bp) alleles were
identified in all organs examined, the null allele Atbf1Δ7&8 (289 bp) was detectable only in the prostatic lobes. AP, anterior prostate. DLP,
dorsal and lateral (dorsolateral) prostate. VP, ventral prostate. (C) Loss of Atbf1 expression in DP of Atbf1PE-/- mice as detected by
immunofluorescent staining. Atbf1 (green) was expressed in the nuclei of prostatic epithelial cells in a 6-month-old Atbf1PE+/+mouse (left
panel), but was lost in the same type of cells in a 6-month-old Atbf1PE-/- mouse (right panel). The nuclei were counterstained with DAPI
(blue). (D) Reduced Atbf1 mRNA levels in DPs of Atbf1PE+/- and Atbf1PE-/- mice as detected by quantitative RT-PCR. *, P b 0.0001.
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performed to evaluate the statistical significance for a difference between
two genotypes.
Gene Expression Profiling and Signaling Pathway Analysis
Dorsal prostate (DP) tissue from 4 Atbf1flox/flox;PB-Cre+ (Atbf1PE-/-)
and 4 Atbf1+/+;PB-Cre+ (Atbf1PE+/+) mice aged 13-15 months was
used in the microarray analysis. After the whole prostate was surgically
isolated, one piece of DP from eachmouse was freshly isolated, weighed
and snap frozen in liquid nitrogen, and the remaining prostatic lobes
were collected for histological analyses.
The microarray experiment was performed by Beckman Counter
Inc (Indianapolis, IN). Briefly, total RNA was extracted from DP
tissues, and the quantity and quality were determined by spectro-
photometry and an Agilent Bioanalyzer (Agilent Technologies, Palo
Alto, CA). Two hundred nanograms of total RNA was converted into
labeled cRNA with nucleotides coupled to fluorescent dye Cy3 using
the Low Input Quick Amp Kit (Agilent Technologies) following the
manufacturer’s protocol. Cy3-labeled cRNA (600 ng) from eachsample was hybridized to an Agilent Mouse Whole Genome 8x60k
Microarray. The hybridized array was then washed and scanned, and
data was extracted from the scanned image using Feature Extraction
version 10.7 (Agilent Technologies).
To remove array specific effects and ensure that signals from different
arrays began at the same baseline, quantile normalization was conducted
on each microarray. Two R packages, siggenes (based on Statistical
Analysis of Microarrays t-test) and MAANOVA (MicroArray ANalysis
Of VAriance) [31], were used to detect differentially expressed genes.
Both software packages use a variance shrinkage approach to improve
detection accuracy by combining information from all genes when
estimating gene level variance. The final reported p-values were from R/
MAANOVA. Genes with an expression fold change of 2 or greater and
false discovery rate (FDR) less than 0.02 were considered differentially
expressed. We then performed pathway analysis using the Ingenuity
Pathway Analysis (IPA) program (http://www.ingenuity.com) (Inge-
nuity Systems, Redwood City, CA) to identify signaling pathways and
networks that were attenuated by Atbf1 deletion. Subcellular
localization of the corresponding proteins was determined based on
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(http://www.plasmaproteomedatabase.org) databases.
Validation of Differentially Expressed Genes by Quantitative
RT-PCR
To validate differentially expressed genes, quantitative RT-PCR was
performed in samples from both the 8DPs used in themicroarray analysis
and additional DPs, including 7 ofAtbf1PE+/+, 10 ofAtbf1PE+/-, and 7 of
Atbf1PE-/-. Briefly, DPs from mice aged at 12 to 15 months were
harvested, and total RNAs were isolated using Trizol reagent (Invitrogen)
following the manufacturer’s instructions. One μg of total RNAwas used
for cDNA synthesis using the iScript reverse transcription kit (Bio-Rad,
Hercules, CA). Quantitative RT-PCR was performed with the SYBR
Premix Ex Taq™ Kit (Clontech Laboratories, Mountain View, CA) and
the ABI Prism 7500 Real-time PCR System (Applied Biosystems,
Carlsbad, California). Relative fold changes were calculated using the
2-ΔΔCt method, with mouse β-actin mRNA as the internal control.
For each gene, PCR primers were designed to generate PCR products
spanning different exons to avoid possible interference from genomic
DNA contamination. Primer sequences and PCR product sizes are
shown in Table S1.
Results
Atbf1 Deletion Leads to Mouse Prostatic Intraepithelial
Neoplasia (mPIN) with Increased Cell Proliferation
Mice with a tissue specific deletion of Atbf1 in prostatic epithelial
cells (Atbf1PE-/-) were generated by breeding floxed Atbf1 mice
(Atbf1flox/+) with PB-Cre4 transgenic mice (Figure 1A). Prostate-
specific deletion of Atbf1 was confirmed by PCR-based genotyping.
In 9-week-old Atbf1flox/+;PB-Cre+ (Atbf1PE+/-) mice, a smaller PCR
product indicating the allele with deletion (Atbf1Δ7&8) was observed
in all prostatic lobes (anterior, dorsal, lateral and ventral prostates) but
not in other organs examined (Figure 1B). Immunofluorescent staining
demonstrated that Atbf1 was predominantly expressed in the nuclei of a
majority of Atbf1PE+/+ prostatic epithelial cells, and Cre-mediated Atbf1
deletion dramatically decreased Atbf1 protein expression in the Atbf1PE-/-
prostate (Figure 1C). Quantitative RT-PCR analysis with cDNA from
the dorsal prostate (DP) at 12-15 weeks showed that hemizygous deletion
of Atbf1 significantly reduced Atbf1 mRNA expression (P b 0.0001)
(Figure 1D), indicating a haploinsufficiency of Atbf1.
To determine the consequence of Atbf1 deletion in the prostate,
we examined a cohort of mice with wildtype Atbf1 (Atbf1PE+/+),
hemizygously deleted Atbf1 (Atbf1PE+/-), and homozygously
deleted Atbf1 (Atbf1PE-/-) aged 3 to 24 months. Most Atbf1PE+/+
mice had a histologically normal prostate phenotype, though a few
developed hyperplasia after 18 months due to aging (Table 1). In
Atbf1PE-/- mice, however, hyperplasia was seen in the dorsal prostate
(DP) at as early as 4 months of age. In these DPs, tufted epithelial cells
formed multiple layers and sometimes a solid bridge across the lumen.
Atypical nuclei were observed at age 6 months (Figure 2A, panels f & j).
By 15months of age, 13 of 21Atbf1PE-/-mice further developedmouse
prostatic intraepithelial neoplasia (mPIN) (Figure 2A, panels g & h). The
DP showed tufted atypical luminal cells, prominent nucleoli, and
abundant pale cytoplasm in the mPIN lesions. Hyperchromasia was
commonly detected and mitotic figures were seen in some cases
(Figure 2A, panel k). Nearly all Atbf1PE-/- mice at age 17-24 months
developed mPIN lesions, and a few showed more severe mPIN lesions as
indicated by poor orientation of unorganized atypical cells, severe
pleomorphism, association with small intraepithelial blood vessels, andhost inflammatory responses (Figure 2A, panels h & l). Simple atrophy
with cystic dilation was also observed in Atbf1PE-/- mice. In addition,
cytoplasmic hyaline was frequently associated with atypia (Figure 2A).
The hyaline structure was not associated with accumulation of glycogen,
since they were negative to Periodic acid-Schiff (PAS) and Alcian blue
(AB) staining (Figure S1). These results indicate that Atbf1 deletion
causes progressive development of precancerous lesions in mouse DPs.
In addition to DP, Atbf1 deletion also caused precancerous lesions in
other lobes of the prostate (Figure 2B). At 9-15 months of age, most
Atbf1PE-/- mice developed hyperplasia or mPIN in the lateral prostate
(LP) and anterior prostate (AP), while the ventral prostate (VP) was least
affected (Table 1). In addition, mice without the Cre transgene (2 each
of Atbf1+/+, Atbf1flox/+ or Atbf1flox/flox), which maintained the wildtype
Atbf1, had no visible hyperplasia or dysplasia by age 12 months,
indicating that Atbf1 deletion caused the histopathologic phenotypes in
Atbf1PE-/- mice. The majority of human prostate cancers (70%) arise in
the peripheral zone and the most analogous part in mice is the DP and
LP [32]. Therefore we focused on the DP for further characterization.
We examined cell proliferation, which is a hallmark for both
cancerous and precancerous lesions, in DP by IHC staining of the
Ki67 proliferation marker. Whereas Ki67 positive cells were rare in
DPs with wildtype Atbf1 (Atbf1PE+/+) or hemizygous deletion of
Atbf1 (Atbf1PE+/-) (0.48% and 0.35% of cells, respectively), they were
significantly more frequent (1.73%) in Atbf1-null (Atbf1PE-/-) DPs
(Figure 3A). The increase in Ki67-positive cells in Atbf1PE-/- mice
indicates accelerated cell proliferation in hyperplasia and mPIN
lesions caused by the Atbf1 deletion (P b or = 0.0001) (Figure 3A).
Atbf1 Deletion Attenuates Basal Cells and the Smooth Muscle
Layer while Maintaining the Luminal Characteristics
Normal prostate contains luminal and basal epithelial cells that are
supported by the fibromuscular layer. To determine whether Atbf1
deletion-induced neoplastic lesions interrupt the structure of the
prostate, we determined the expression of several molecular markers for
different types of cells in the prostate by IHC staining (Figure 3B).
Compared to normal prostates, Atbf1 deletion-induced mPIN lesions
had reduced or absent expression of the basal cell marker cytokeratin 5
(Ck5), suggesting the attenuation of basal cells by Atbf1 deletion. The
epithelial adhesion protein E-cadherin (Cdh1), which was uniformly
detected in prostatic epithelia of wildtype mice, was also decreased or
absent once Atbf1 was deleted (Figure 3B). The expression pattern of
smoothmusclemarker Sma (smoothmuscle actin) was also decreased or
absent in the smooth muscle layer, indicating its attenuation by Atbf1
deletion (Figure 3B).
In the tufted cells of mPIN induced by Atbf1 deletion, luminal cell
markers cytokeratin 18 (Ck18) and androgen receptor (Ar) were
expressed as in normal prostatic epithelial cells (Figure 3B), indicating
a luminal characteristic of mPIN lesions induced by Atbf1 deletion.
Neuroendocrine cells, which were detected by synaptophysin (Syn)
staining, were rarely seen in both genotypes.
Atbf1 Deletion in Mouse Prostates Dysregulates a Number of
Genes, Particularly those that Encode for Secretory and Cell
Membrane Proteins
As a transcription factor, Atbf1 regulates the expression of many genes.
To understand what genes are dysregulalted by Atbf1 deletion, we
conducted a microarray analysis using DPs from 8mice at 13-15 months
of age, 4 with wildtype Atbf1 (Atbf1PE+/+) and 4 with homozygous
deletion of Atbf1 (Atbf1PE-/-). Histological analysis confirmed normal
prostatic phenotypes in the Atbf1PE+/+ mice and hyperplasia and mPIN
Table 1. Differences in Atbf1 deletion-induced phenotype among prostatic lobes at different ages.
Prostatic
lobes
Age
(Months)
Atbf1
alleles
Mice with different phenotypes (n) Total
(n)
Normal Hyperplasia mPIN
Dorsal +/+ 6 6
4-7 +/- 3 1 6
-/- 15 3 18
+/+ 21 21
9-15 +/- 15 6 1 22
-/- 8 13 21
+/+ 7 7 14
17-24 +/- 4 12 3 19
-/- 1 16 17
Lateral +/+ 6 6
4-7 +/- 6 6
-/- 9 4 13
+/+ 17 5 22
9-15 +/- 10 9 2 21
-/- 4 14 2 20
+/+ 6 7 1 14
17-24 +/- 11 8 1 20
-/- 1 4 10 15
Anterior +/+ 6 6
4-7 +/- 5 1 6
-/- 8 10 18
+/+ 20 1 21
9-15 +/- 16 6 22
-/- 8 10 3 21
+/+ 9 6 15
17-24 +/- 6 10 3 19
-/- 3 5 8 16
Ventral +/+ 6 6
4-7 +/- 5 5
-/- 17 17
+/+ 22 22
9-15 +/- 21 21
-/- 12 8 20
+/+ 11 3 14
17-24 +/- 18 1 19
-/- 3 6 7 16
Notes: mPIN, mouse prostatic intraepithelial neoplasia; + and – indicate the presence and absence
of an Atbf1 allele respectively.
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hybridized to an Agilent mouse whole genome 8x60k chip, which
covers 39,430 Entrez genes and 16,251 lincRNAs. After quantile
normalization, gene expression was analyzed by two R computer
programs, siggenes and MAANOVA, and the two programs generated
similar results with a correlation of 0.97. A supervised gene list was
generated using R/MAANOVA.With a false discovery rate at 0.02 and
a fold change of 2 or greater, a total of 445 probes were differentially
expressed in Atbf1PE-/- DPs, representing 176 upregulated and 215
downregulated) genes (some genes were represented by two or more
probes on the microarray) (Table S2).
To validate differential expression of the genes between normal
prostates and mPIN, we performed quantitative RT-PCR on a total of
32 samples, including 11 for Atbf1PE+/+, 10 for Atbf1PE+/-, and 11 for
Atbf1PE-/- mice. Twenty-six of 30 up-regulated and 5 of 6 down-
regulated genes were confirmed with statistical significance (P b 0.05)
(Figure 4A, B and Table S3). A number of these molecules have been
associated with cancer development. We selected two up-regulated
genes, Spink3 and Clu, and confirmed their elevated protein expressionin Atbf1PE-/-DP by IHC (Figure 4C). Among the 30 validated genes, 7
(Mcm10, Gabra4, Gabrb1, Rgs2, Serpinb11, St3gal3 and Col4a6) were
also differentially expressed in Atbf1PE+/- mice compared to wildtype
mice, further indicating the haploinsufficiency ofAtbf1 in the regulation
of a subset of its target genes (Figure 4A).
Notably, a number of the dysregulated genes encode secretory proteins
or cell membrane proteins. Among the 391 differentially expressed
proteins, 64 (16.4%) were annotated as secretory proteins, includingClu,
Timp4, Wnt4, C1ra and Col4a6, and 101 (25.8%) were reportedly
localized to the cytoplasmic membrane, including Trpv6, Prlr, Tacstd2,
Slc12a8 and Ptger3 (Table S2). In addition, 117 of the 391 differentially
expressed proteins (29.9%) have been detected in the plasma or serum,
according to the Plasma Proteome database (Table S2).
Membrane proteins play essential roles in different cellular
processes, and their abnormal expression and modification often
occur during cancer development. One family of such proteins are
mucins, which have an aberrant and unique expression pattern in
cancer cells and thus have been used as diagnostic markers as well as
therapeutic targets [33,34]. Mucin 1 (MUC1) is an O-glycosylated
transmembrane glycoprotein which primarily hydrates, lubricates and
protects the epithelial luminal surfaces of ducts [35]. Its core peptide is
attached with a number of O-glycans in normal cells but the level of
glycosylation is reduced in tumors, leading to the exposure of epitopes for
immunodetection and cytoplasmic localization of MUC1 [35,36].
Therefore, we examined Muc1 expression, and found that Muc1 was
significantly upregulated in Atbf1 deletion-induced neoplastic lesions
(Figure 3B). The increase in Muc1 expression in the cytoplasm has been
associated with alterations in its glycosylation [35], and the Tn antigen, a
truncated mucin-type O-glycan, is often overexpressed in human
malignancies including prostate cancer [37]. We examined the expression
of Tn antigen by immunostaining of prostates with both Helix pomatia
agglutinin (HPA), a snail lectin which recognizes Tn antigen of
glycoproteins, and an anti-Tn monoclonal antibody. Strong staining for
Tn antigen was detected in Atbf1PE-/- DP but not in Atbf1PE+/+ DP,
indicating that Atbf1 deletion increased Tn antigen expression
(Figure 3B).
Atbf1 Deletion Attenuates Multiple Signaling Pathways
Including the Activation of Erk1/2 AKT Oncogenic Signaling
We then input genes differentially expressed between prostates with
and without Atbf1 deletion, along with their expression levels, into the
Ingenuity Pathway Analysis (IPA) program to identify functional
networks and signaling pathways that are affected by Atbf1 deletion.
Several were identified to have statistically significant P values, and
multiple biological processes were affected, including cell differentia-
tion, tissue development, cell death, cell movement, secretion of bodily
fluid, cation transport, atrial fibrillation and blood pressure regulation
(Table S4). All these functions are associated with signals mediated by
extracellular and cell membrane molecules. The four networks with the
smallest P values are shown in Figure 5, which included those centered
ERK1/2 and IGF1 (Figure 5A), Akt and FSH (Figure 5B), NF-κB
(Figure 5C) and progesterone and β-estradiol (Figure 5D). Although no
canonical pathways were predicted with statistical significance, all four
of these networks play a role in cancer development.
ERK and AKT are frequently activated during carcinogenesis, so we
examined whether they are activated by Atbf1 deletion. Using IHC
staining, we found that phosphorylated Erk1/2 and Akt, which represent
the activated Erk1/2 and Akt, were clearly detected inAtbf1-null DPs but
were undetectable in DPs with wildtype Atbf1 (Figure 3B).
Figure 2. Development of mouse prostatic intraepithelial neoplasia (mPIN) in Atbf1PE-/- prostates. (A) Representative hematoxylin
and eosin (HE)-stained mouse tissue sections from dorsal prostates (DPs) with wildtype (Atbf1PE+/+) (a-d) and null Atbf1 (Atbf1PE-/-) (e-h) at
3, 6, 12 and 24 months. Images in i-l are magnified areas of the marked rectangles in images e-h respectively. Note that DPs with Atbf1
deletion (Atbf1PE-/-) show normal prostate (e & i), hyperplasia (f & j) and mPIN (g, h, k, & l) at 3, 6, 12 and 24 months respectively. A mitotic
figure is indicated by an arrow in k. The inset at the upper right corner of h is the magnified area of the nearby square, showing
intraepithelial red blood cells. Arrowheads in j-l indicate cytoplasmic hyaline associated with atypia. (B) Representative HE-stained tissue
sections frommouse lateral prostates (LPs), anterior prostates (APs) and ventral prostates (VPs). Atbf1PE+/+ mice had normal histological
phenotypes in these lobes (a-c). Hyperplasia was sometimes detected in Atbf1PE+/- mice (d and e), whereas mPIN was observed in all
three lobes with homozygous deletion of Atbf1 (Atbf1PE-/-) (g-i). All scale bars are 100 μm.
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Atbf1 Deletion Induces mPIN in Mouse Prostates
While a tumor suppressor function of ATBF1 has been suggested by
its frequent chromosomal deletion at 16q22 and somatic mutations inhuman cancers [8–10], the effect ofAtbf1 inactivation on tumorigenesis
has not been tested in a mouse model because conventional deletion of
Atbf1 in mice is embryonic lethal and loss of even one allele of Atbf1
results in preweaning mortality and partial embryonic lethality [7]. In
this study, we used the Cre-loxP system to specifically delete Atbf1 in
Figure 3. Cell proliferation analysis and molecular characterization of mPIN lesions induced by homozygous deletion of Atbf1.
(A) Evaluation of cell proliferation by detecting Ki67-positive cells with immunohistochemicial staining. The percentage of Ki67-positive
cells in the epithelium of a DPwas plotted against Atbf1 genotype (circular-, squared- and triangle-shaped boxes for Atbf1PE+/+, Atbf1PE+/-
and Atbf1PE-/- respectively), and mean values are indicated by horizontal lines. An increase in Ki67-positive cells is seen in hyperplasia and
mPIN lesions. *, P=0.0001. **, P b 0.0001. (B) Homozygous deletion of Atbf1 (Atbf1PE-/-) changed the expression of molecules involved in
different characteristics of prostate and prostate cancer, including luminal-basal-stroma architectural markers cytokeratin 5 (Ck5), Ck18,
E-cadherin (Cdh1) and smooth muscle actin (Sma); epithelial differentiation markers androgen receptor (Ar); oncogenic signaling
molecules phospho-Erk1/2 (p-Erk1/2) and phospho-Akt (p-Akt); and glycoprotein mucin 1 (Muc1) and glycosylation marker Tn antigen (the
upper and lower Tn panels were detected by the antibody and HPA methods respectively). DPs with mPIN from 24-month-old mice were
used for Ck5, Ck18, E-cadherin, Sma and Ar, while those of 12-month-old mice were used for p-Erk1/2, p-Akt, Muc1 and Tn antigen.
Immunofluorescent staining with nuclei counterstained with DAPI (blue) was used for Tn detection, while immunohistochemcial staining
was performed for the rest of the molecules. Note the attenuation or loss of Ck5, Cdh1 and Sma, as indicated by arrows and magnified
regions at the upper right corner of respective images. Also note the appearance of both p-Erk1/2 and p-Akt (pointed by arrows) and
significant increase in Muc1 and Tn antigen expression in mPIN lesions with Atbf1 deletion. All scale bars are 100 μm.
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mPIN in mice, providing for the first time direct evidence for a tumor
suppressor function of Atbf1. Hyperplasia was detected as early as 4
months of age, and mPIN occurred when Atbf1PE-/- mice aged. Atbf1
deletion-induced mPIN had established mPIN features such asprominent nucleoli, abundant pale cytoplasm, severe pleomorphism,
association with host inflammatory responses, and discontinuity of the
fibromuscular sheath [27]. Another feature in the Atbf1-null mPINwas
severe atypic cytoplasmic hyaline, which is seen sometimes in human
prostate cancer [38] but rarely in mPIN induced by the knockout of
Figure 4. Validation of dysregulated genes by homozygous deletion of Atbf1 in mouse dorsal prostates (DPs). Expression of
upregulated (A) and downregulated genes (B) was analyzed by real-time RT-PCR (A, B), with 2 genes’ protein expression also evaluated by
immunohistochemical staining (C). In the real-time RT-PCR assay, the relative gene expression levels were plotted as circular (Atbf1PE+/+),
squared (Atbf1PE+/-) and triangle (Atbf1PE-/-) shaped boxes respectively, and mean values are indicated by lines. For each gene, the
average expression level in Atbf1PE+/+was set to 1, and levels in each individual were adjusted accordingly. Asterisks indicate two genes
(Gabra4 andMcm10) expressed at intermediate levels in Atbf1PE+/- mice, which indicates haploinsufficiency for these genes. Scale bars
in panel C are 100 μm.
384 Deletion of Atbf1 causes mPIN in mouse prostates Sun et al. Neoplasia Vol. 16, No. 5, 2014other tumor suppressor genes [27]. In human prostates, PIN has been
widely considered as a precursor of prostate adenocarcinoma [39], and
many known oncogenic genetic events induce mPIN rather than
invasive carcinoma in mouse prostates [40,41]. Therefore, induction of
mPIN by Atbf1 deletion provides functional evidence for Atbf1 tumor
suppressor activity.No invasive prostate cancer was detected in any of theAtbf1PE-/-mice
even at 25 months old, which has been common for many known
tumor suppressor genes including p53, Rb,Nkx3.1,Maspin, Brca2 and
p27Kip, whose deletion alone also only causes mPIN lesions [42–47]. It
is well recognized that multiple genetic and epigenetic alterations are
usually required for an invasive cancer to develop. While Atbf1 deletion
Figure 5. Identification of molecular pathways that are altered by Atbf1 inactivation in mouse prostates. Genes differentially
expressed between Atbf1-positive and Atbf1–negative prostates, along with their expression levels, were imported to the Ingenuity
Pathway Analysis (IPA) program to construct interacting pathways. The four networks with the smallest P values are shown. The intensity
of the node color indicates the degree of upregulation (red) or downregulation (green) in Atbf1-null prostates. Solid and dashed lines
indicate direct and indirect interactions respectively. Different shapes of the nodes, including square, circle, diamond, rectangles etc.,
represent functional classification of the genes.
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cooperate with other oncogenic events to induce invasive carcinoma. We
are in the process of testing whether Atbf1 deletion cooperates with Pten
deletion, a well characterized oncogenic event in prostate cancer [48], in
the development and progression of prostate cancer.
Atbf1 Deletion-Induced mPIN Lesions Share Multiple
Morphological and Molecular Characteristics with Human
Prostate Cancer
Mouse DP is anatomically and biochemically closest to the
peripheral zone of human prostate [49], and most human prostate
cancers arise from the peripheral zone of prostate [50]. Thus finding
of the most severe histopathological lesions in the DP of Atbf1PE-/-
mice (Figures 1, 2) indicates a reasonable relevance of Atbf1 deletion-
induced mPIN to human prostate cancer. Another histological
change that also occurs in human prostate cancer is the interruption
of the fibromuscular layer in Atbf1 deletion-induced mPIN lesions, asindicated by attenuated expression of the Sma smooth muscle marker
(Figure 3B).
Shared cellular and molecular characteristics further indicate the
relevance of Atbf1 deletion-induced mPIN lesion to human prostate
cancer. One shared characteristic is increased cell proliferation, as
indicated by the increase in Ki67-positive cells in Atbf1-null prostates
(Figure 3A). In human prostate cancer, an increased Ki67 proliferation
index correlates with higher tumor grade and worse patient survival
[51]. Atbf1 deletion-induced mPIN lesions also maintained luminal
characteristics as seen in most human prostate cancers, indicated by the
positive staining of luminal markers Ck18 and Ar and decreased
staining of the Ck5 basal cell marker (Figure 3B).
Multiple molecular alterations reported in human prostate cancer
also occurred in Atbf1 deletion-induced mPIN lesions. For example,
the cell-cell adhesion molecule E-cadherin, which is often downreg-
ulated in human prostate cancer [52], was also downregulated in
mPIN lesions induced by Atbf1 deletion (Figure 3B). Increased
386 Deletion of Atbf1 causes mPIN in mouse prostates Sun et al. Neoplasia Vol. 16, No. 5, 2014expression of activated Erk1/2 and Akt (i.e., phosphorylated Erk1/2
and Akt), which mediate two common oncogenic signaling pathways
and often occur in human prostate cancer and other mouse models
of prostate cancer [53–56], was also detected in Atbf1-null mPIN
(Figure 3B). Another example is the upregulation of Muc1 by
Atbf1 deletion (Figure 3B), which also occurs in human primary
and metastatic prostate cancers and suggests Muc1 as a potential
therapeutic target for cancer treatment [33,35,36]. MUC1 is a major
cell surface protein that functions as a physical and biological barrier to
protect mucous epithelia, and interacts with a number of proteins to
trigger diverse signaling pathways including the MAPK/ERK pathway
[33,57]. Overexpression ofMuc1 alone in mouse mammary glands can
also lead to increased ERK1/2 activity [58]. Thirdly, Atbf1 deletion led
to the expression of the Tn antigen (Figure 3B), an O-glycan that is
usually found on cancer cells but not on normal cells [29,59]. Altered
glycosylation in cancer cells could affect MUC1 distribution and
signaling [35]. These molecular similarities between Atbf1 deletion-
induced mPIN lesions and human prostate cancer indicate the model’s
intrinsic relevance.
Atbf1Deficiency Attenuates the Secretory Profile ofMouse Prostates
ATBF1 is a transcription factor, and we would thus expect thatAtbf1
deletion in mouse prostates dysregulates a number of genes. This is
indeed the case, as hundreds of genes, 391 of which are protein-coding,
were differentially expressed between normal prostates and Atbf1-null
prostates (Table S2). Some differentially expressed genes, including
Clu, Qsox1, Hk2 and Tacstd2, were also identified in mouse prostates
with the knockout of Nkx3.1 or Pten, both of which have a tumor
suppressor function in prostate cancer [48,60,61]. Interestingly, 64 of
the 391 (16%) differentially expressed proteins were annotated as
secretory proteins and 117 of them (29.9%) have been detected in the
plasma or serum (Table S2). We verified the elevation of two secretory
proteins, Clu and Spink3, by IHC staining in mouse DPs. Clu was also
up-regulated in Nkx3.1 and Pten-deficient mouse prostates and has
been implicated in increased prostate cancer resistance to chemotherapy
[48,61,62]. SPINK1, the human homolog of Spink3, was overexpressed
in a subset of ETS rearrangement-negative prostate cancers, and its
reduced expression in 22Rv1 prostate cancer cells attenuates cell invasion
[63,64]. In a preliminary experiment, we used liquid chromatography
coupled with tandem mass spectrometry (LC-MS/MS) to identify
secretory proteins inmouse prostates, and found several secretory proteins
that were differentially expressed between the wildtype and Atbf1PE-/-
mice (data not shown), supporting the conclusion from the microarray
study. Dysregulation of a large number of secretory proteins by Atbf1
deletion thus suggests an important role of Atbf1 in the structure and
function of the adult prostate. For example, Atbf1 could be necessary for
the induction and/ormaintenance of differentiated secretory luminal cells
in the prostate. Supporting this idea, a role for ATBF1 has been detected
in neuronal differentiation [65,66].
Atbf1 Deletion Leads to Abnormalities in Multiple Signaling
Pathways Involved in Carcinogenesis
Some of the secretory proteins dysregulated by Atbf1 deletion,
including Igf1 (Tables S2), are known signaling molecules. In addition,
101 of the 391 (25.8%) differentially expressed proteins between normal
and Atbf1-null prostates have been reported as membrane proteins
(Table S2), including receptors (e.g., Prlr and Ptger3), cell surface
antigens (e.g., Ly6e), and ion channels and transporters (e.g., Slc22a4,
Trpv6, and Atp12a) (Table S2). Ion channel and transporter proteinsaffect the concentration of extracellular and intracellular cations to
regulate a broad range of biological events related to cancer, including cell
proliferation, apoptosis and migration [67]. Whereas some of the ion
channel proteins are dysregulated in human prostate cancer, e.g., TRPV6
is upregulated in advanced prostate tumors to increase Ca2+ entry [68],
many of the differentially expressed proteins such as PrlR and RGS3 are
known to influence cellular signaling. It is thus possible that Atbf1
deletion attenuates multiple signaling pathways and networks, and the
pathway analyses supports this predication (Figure 5, Table S4).
When differentially expressed genes between normal and Atbf1-
null prostates and their expression levels were examined with the
Ingenuity Pathway Analysis (IPA) program, a number of signaling
pathways/networks were identified (Table S4), and these pathways
regulate multiple biological processes including cell differentiation,
tissue development, cell death, cell movement, secretion of bodily
fluid, cation transport, atrial fibrillation and blood pressure regulation
(Table S4). The four with the highest statistical significance centered
on ERK1/2-IGF1, AKT-FSH, NF-κB and progesterone-β-estradiol
(Figure 5), and each of these four networks has been implicated in
cancer development. For example, activated ERK1/2 and AKT, two
well established oncogenic molecules that can be activated by a number
of genetic events during carcinogenesis, were also detectable in Atbf1
deletion-induced mPIN lesions (Figure 3B).
For the network centered on ERK1/2 and IGF1, there were multiple
molecules linking them (Figure 5A), but whether and how these two
nodes truly interact are unknown, although higher serum concentra-
tions of IGF1 are associated with an increased risk of several types of
cancers including prostate cancer [69], and IGF1 signaling involves the
activation of ERK1/2 [70]. For the network centered on follicle-
stimulating hormone (FSH) and AKT (Figure 5B), the FSHhormone is
known to act on granulosa cells within the immature follicle to promote
proliferation, inhibit apoptosis, and stimulate hormone production; and
multiple signaling pathways including the PI3K/AKT pathway are
involved in FSH function [71,72]. FSH also stimulates the PI3K-
dependent pathway in the proliferation and differentiation of Sertoli
cells [73,74] and meiotic maturation of oocytes [75]. Interestingly, in
addition to androgens, FSH is another hormone that influences the
pathogenesis and progression of prostate cancer, as FSH and its
receptors are upregulated in prostate cancer and the serum level of FSH
is associated with extraprostatic extension of prostate cancer [76,77].
Therefore, increased FSH hormonal signaling activity and subsequent
PI3K/AKT activation could be one of the major pathways that mediate
the effect of Atbf1 deletion on prostatic tumorigenesis.
Another signaling network attenuated by Atbf1 deletion focused
on NF-κB (Figure 5C), which often has increased activity in human
cancers and thus has been considered a therapeutic target in cancer
treatment [78]. In human prostate cancer, NF-κB is constitutively
active in a subset of castration-resistant prostate cancers, and NF-κB
overexpression significantly associates with shorter patient survival
[79,80]. Human prostate cancer cell lines also have constitutively
active NF-κB [81], and inhibition of NF-κB activity inhibited their
growth in xenograft models, decreased bone resorption of prostate
cancer cells co-cultured with bone marrow, and reduced their invasive
capability [82,83]. Interestingly, ATBF1 is the second most frequently
mutated gene in castration-resistant human prostate cancer [9,10].
Taken together, it is possible that inactivation of ATBF1 in human
prostate cancer activates NF-κB signaling to induce and/or promote the
progression of prostate cancer to an androgen-independent and/or
metastatic state.
Neoplasia Vol. 16, No. 5, 2014 Deletion of Atbf1 causes mPIN in mouse prostates Sun et al. 387Surprisingly, the fourth most affected signaling network by Atbf1
deletion was the estrogen-progesterone signaling network (Figure 5D).
The presence of estrogen and progesterone receptors in prostate cancer
has been documented [84], and so has the role of estrogen in the
development and progression of prostate cancer [85,86]. For example,
androgen-responsive LNCaP prostate cancer cells are stimulated by
estradiol for growth via estrogen receptors while the androgen-insensitive
PC-3 prostate cancer cell proliferation is inhibited by estrogen [85].
Human prostate expresses both ERα and ERβ, which are dysregulated
during the development and progression of prostate cancer. ERα is often
upregulated to mediate the oncogenic effects of estradiol, which also
involves the estrogen-regulated progesterone receptor (PR), during
prostate cancer progression [87]. On the other hand, ERβ is
downregulated in castration-resistant prostate cancer and thus
serves as a tumor suppressor [87]. ERβ mediates the inhibitory
effect of antiestrogens on the development of castration-resistant prostate
cancer by interacting with other transcription factors to upregulate
FOXO1, inducing anoikis and thus suppressing the growth of
prostate cancer [88].
The role of estrogen and progesterone in prostate cancer is better
documented in mouse models [86]. Further supporting the effect of
Atbf1 deletion on estrogen signaling, our previous studies demonstrated
that in breast cancer cells estrogen signaling upregulates ATBF1
transcription but causes ATBF1 protein degradation [89,90], while
ATBF1 inhibits ERα function by selectively competing with one of its
coactivators for the binding to ERα [91]. Atbf1 deletion increased cell
proliferation only in ERα-positive but not in ERα-negative cells [92]
and the Pg-progesterone signaling upregulates ATBF1 in mammary
epithelial cells [93]. All these findings suggest the possibility that Atbf1
suppresses ERα signaling in normal prostates and Atbf1 deletion leads
to more active estrogen signaling that could promote the development
and progression of prostate cancer.
The fifth most significant network based on the P value was the
network of 9 genes involved in atrial fibrillation (Table S4), a common
heart rhythm disorder. The role of ATBF1 in atrial fibrillation has been
suggested by a genetic association of ATBF1 sequence variants with this
disorder [5,6], and the 9 genes regulated by Atbf1 provide a clue for how
ATBF1 mutation may modulate atrial fibrillation.
In summary, we found that deletion of Atbf1 in mouse prostates
caused mPIN lesions, and the mPIN lesions shared a number of
histopathologic and molecular features with human PIN and prostate
cancer, providing functional evidence for a tumor suppressor activity of
ATBF1 in human prostate cancer and establishing a mouse model of
prostatic carcinogenesis that is relevant to human prostate cancer. In
addition, a number of genes, particularly those encoding for cell
membrane and secretory proteins, were dysregulated by Atbf1 deletion,
and the most affected signaling networks centered on Erk1/2 and IGF1,
Akt and FSH,NF-κB and progesterone and β-estradiol, all of which have
been implicated in human cancer development. These findings provide
in vivo evidence that ATBF1 is a tumor suppressor in the prostate,
suggest that loss of Atbf1 contributes to tumorigenesis by dysregulating
membrane and secretory proteins and multiple signaling pathways, and
provide a new and clinically relevant animal model for prostate cancer.
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